ETF Holdings Breakdown of RNA

News associated with RNA

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC lifted its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 111.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 17,519 shares of the biotechnology company’s stock after buying an additional 9,230 shares during the quarter. Hsbc Holdings PLC’s holdings in Avidity Biosciences were worth $507,000 at the end […] - 2025-05-07 08:00:55

First Trust Advisors LP Buys 45,254 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

First Trust Advisors LP lifted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 110.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 86,395 shares of the biotechnology company’s stock after acquiring an additional 45,254 shares during the period. First Trust Advisors LP […] - 2025-05-05 08:08:59

Envestnet Asset Management Inc. Sells 3,931 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

Envestnet Asset Management Inc. decreased its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 33,132 shares of the biotechnology company’s stock after selling 3,931 shares during the quarter. Envestnet […] - 2025-05-02 07:24:46

Raymond James Financial Inc. Makes New $5.78 Million Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)

Raymond James Financial Inc. purchased a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 198,907 shares of the biotechnology company’s stock, valued at approximately $5,784,000. Other hedge funds and […] - 2025-04-25 09:43:06

Legal & General Group Plc Has $2.97 Million Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)

Legal & General Group Plc lifted its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 7.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 102,100 shares of the biotechnology company’s stock after purchasing an additional 6,937 shares […] - 2025-04-24 08:06:51

Summit Investment Advisors Inc. Buys 666 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

Summit Investment Advisors Inc. raised its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 6.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,611 shares of the biotechnology company’s stock after purchasing an additional 666 shares during the period. […] - 2025-04-21 07:56:51

Renaissance Technologies LLC Acquires 69,300 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

Renaissance Technologies LLC lifted its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 48.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 211,200 shares of the biotechnology company’s stock after acquiring an additional 69,300 shares during the period. Renaissance […] - 2025-04-20 08:00:56

Alliancebernstein L.P. Decreases Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

Alliancebernstein L.P. decreased its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 25.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,770 shares of the biotechnology company’s stock after selling 42,914 shares during the quarter. Alliancebernstein L.P.’s holdings in Avidity […] - 2025-04-15 07:50:50

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its position in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 3.6% in the 4th quarter, Holdings Channel reports. The firm owned 450,144 shares of the biotechnology company’s stock after selling 16,941 shares during the period. JPMorgan Chase & Co.’s holdings in Avidity Biosciences were worth $13,090,000 as of its […] - 2025-04-14 08:13:06

Needham & Company LLC Reaffirms “Buy” Rating for Avidity Biosciences (NASDAQ:RNA)

Avidity Biosciences (NASDAQ:RNA – Get Free Report)‘s stock had its “buy” rating restated by Needham & Company LLC in a report released on Wednesday,Benzinga reports. They currently have a $60.00 target price on the biotechnology company’s stock. Needham & Company LLC’s target price would indicate a potential upside of 148.86% from the stock’s current price. […] - 2025-04-11 09:22:53

Sei Investments Co. Sells 19,149 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

Sei Investments Co. lessened its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 47.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 21,554 shares of the biotechnology company’s stock after selling 19,149 shares during the period. Sei Investments Co.’s holdings in Avidity Biosciences were worth $627,000 as of its most […] - 2025-04-09 07:28:50

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Schroder Investment Management Group

Schroder Investment Management Group boosted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 99.7% in the fourth quarter, Holdings Channel reports. The fund owned 61,480 shares of the biotechnology company’s stock after purchasing an additional 30,697 shares during the period. Schroder Investment Management Group’s holdings in Avidity Biosciences were worth […] - 2025-04-07 08:46:59

Mitsubishi UFJ Asset Management Co. Ltd. Has $171,000 Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

Mitsubishi UFJ Asset Management Co. Ltd. decreased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 36.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,621 shares of the biotechnology company’s stock after selling 3,292 shares during […] - 2025-04-04 08:55:03

KLP Kapitalforvaltning AS Acquires New Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

KLP Kapitalforvaltning AS purchased a new position in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 17,900 shares of the biotechnology company’s stock, valued at approximately $521,000. Other institutional investors and hedge funds […] - 2025-04-04 07:46:49

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC lowered its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 6.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,525 shares of the biotechnology company’s stock after selling 731 shares during the quarter. […] - 2025-04-01 07:32:50

Cibc World Markets Corp Acquires New Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

Cibc World Markets Corp bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,386 shares of the biotechnology company’s stock, valued at approximately $302,000. A number of other […] - 2025-03-25 08:48:52

Raymond James Financial Inc. Acquires Shares of 198,907 Avidity Biosciences, Inc. (NASDAQ:RNA)

Raymond James Financial Inc. bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 198,907 shares of the biotechnology company’s stock, valued at approximately $5,784,000. Other hedge funds have also recently made changes to their positions in the company. Victory Capital Management Inc. […] - 2025-03-25 08:08:48

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $66.69 Average Target Price from Analysts

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the thirteen research firms that are covering the company, MarketBeat.com reports. Thirteen analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have covered the stock in the last year is […] - 2025-03-21 05:20:54

Chardan Capital Reaffirms Buy Rating for Avidity Biosciences (NASDAQ:RNA)

Chardan Capital reissued their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note published on Monday,Benzinga reports. The firm currently has a $65.00 price target on the biotechnology company’s stock. Other analysts have also recently issued research reports about the company. Scotiabank began coverage on Avidity Biosciences in a […] - 2025-03-18 05:54:46

Avidity Biosciences (NASDAQ:RNA) Earns Sector Outperform Rating from Analysts at Scotiabank

Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, MarketBeat Ratings reports. The brokerage issued a sector outperform rating and a $70.00 target price on the biotechnology company’s stock. Other analysts also recently issued research reports about the company. Chardan Capital reaffirmed a “buy” rating […] - 2025-03-10 05:50:51

Avidity Biosciences (NASDAQ:RNA) Shares Gap Down After Analyst Downgrade

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report)’s stock price gapped down before the market opened on Monday after Barclays lowered their price target on the stock from $63.00 to $57.00. The stock had previously closed at $30.64, but opened at $29.90. Barclays currently has an overweight rating on the stock. Avidity Biosciences shares last […] - 2025-03-04 06:37:23

Barclays Cuts Avidity Biosciences (NASDAQ:RNA) Price Target to $57.00

Avidity Biosciences (NASDAQ:RNA – Free Report) had its target price cut by Barclays from $63.00 to $57.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the stock. Needham & Company LLC reissued […] - 2025-03-03 06:48:54

New York State Common Retirement Fund Buys 598 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

New York State Common Retirement Fund raised its stake in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 0.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 184,811 shares of the biotechnology company’s stock after acquiring an additional 598 shares during the period. […] - 2025-02-28 09:04:58

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lifted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 8.1% during the fourth quarter, Holdings Channel reports. The firm owned 48,536 shares of the biotechnology company’s stock after buying an additional 3,638 shares during the period. State of New Jersey Common Pension […] - 2025-02-26 08:31:05

Analysts Set Avidity Biosciences, Inc. (NASDAQ:RNA) PT at $65.80

Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) have earned a consensus recommendation of “Buy” from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. Ten analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last […] - 2025-02-24 06:30:54

abrdn plc Buys 20,076 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

abrdn plc raised its stake in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 80.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,912 shares of the biotechnology company’s stock after purchasing an additional 20,076 shares during the period. abrdn plc’s holdings in […] - 2025-02-11 08:24:48

RNA institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	54,826	USD 1,572,958
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	39,830	USD 1,142,723
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	57,237	USD 1,642,130
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	57,237	USD 1,642,130
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	969	USD 27,801
Total =		210,099	USD 6,027,742

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer